Ethylene Diamine Tetraacetic Acid (EDTA) Nasal Spray

(Ship Cold)

Available Dosage Strengths

0.25% (0.25 mg/Spray) | 0.5% (0.5 mg/Spray)

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Ethylene Diamine Tetraacetic Acid (EDTA) Nasal Sray

Product Overview

Description

Ethylenediaminetetraacetic Acid (EDTA) Nasal Spray Description^1,2 

EDTA has many potential medicinal uses. It may be effective as a chelating agent to treat increased calcium in the body and heavy metal poisoning including lead poisoning. It also has been used as an anticoagulant for laboratory hematological tests. EDTA may also be used to prevent microbial growth for central venous lines as a lock solution, and it may prevent the formation of biofilms that are formed by bacterial pathogens especially for chronic rhinosinusitis. As an agent to treat biofilms for chronic sinus infections, EDTA has been administered as a nasal spray and has the following benefits:

Effective against biofilms produced by the bacteria (S. aureus (irrespective of methicillin resistance status), P. aeruginosa, E. coli, K. pneumoniae and Serratia marcescens) as well as Candida albicans and fungi (Candida glabrata)
Shown to potentiate the effectiveness of antimicrobials

Mechanism of Action

Mechanism of Action^1,2 

EDTA works on sinus infections by weakening the extracellular matrix of the biofilm by sequestering the cations (calcium, magnesium, and zinc) required to maintain the structure of the biofilm. Once the biofilm is destabilized the immune system and antimicrobials can better work to treat the infection.

Adverse Reactions

EDTA^1,2   

Common

Rash and a histamine-like reaction consisting of headache, sneezing, nasal congestion, and lacrimation

Contraindications & Precautions

Contraindications^1,2 

Hypersensitivity or intolerance to EDTA or excipients
Patients with hepatitis
Systematic administration not recommended during pregnancy—check with health care provider about effects during pregnancy

Precautions^1,2 

Caution in patients with renal dysfunction

Storage

Store at 2°C–8°C (36°F–46°F)
Protect from light, heat, and moisture

References

Clinical Pharmacology EDTA clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Hale SJM, Wagner Mackenzie B, Lux CA, Biswas K, Kim R, Douglas RG. Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review. Front Pharmacol. 2022 Jun 13;13:840323.

Disclaimer

This information is for educational purposes only. This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness. This product is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding treatment, cure, or prevention of any disease or condition.

This information may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.